ArticleEuropean journal of pediatrics2026
Nirsevimab reduced acute otitis media infections in infants-a nationwide interrupted time-series analysis.
Article in European journal of pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Respiratory syncytial virus (RSV) is a major cause of acute respiratory tract infections in young children worldwide. Acute otitis media (AOM) is among the most frequent complications of RSV infection and the leading indication for antibiotic prescribing in this age group. The aim of this study was to evaluate the effectiveness of nirsevimab in reducing the incidence of AOM among infants. We conducted a nationwide register-based interrupted time-series study using data on live births, laboratory-confirmed RSV detections, and AOM diagnoses from four consecutive RSV seasons (2022-2023 to 2025-2026). Monthly infant populations at risk were reconstructed from birth cohorts to estimate incidence rates during the peak RSV seasons (December-March) which were compared between two pre-implementation and two post-implementation RSV seasons in infants aged < 12 months, stratified into age groups of 0-2, 3-5, and 6-11 months. The study population consisted of 181,999 infants and the follow-up consisted of 2,022,261 infant-months. A total of 3699 RSV-positive findings and 15,830 AOM diagnoses were included in the primary analysis. Following nirsevimab implementation, the incidence of AOM and RSV among infants aged < 12 months decreased by 44% (RR 0.56, 95% CI 0.54-0.58) and 83% (RR 0.17, 95% CI 0.15-0.18), respectively. The reduction was greatest in the youngest age (0-2 months) group.
conclusionImplementation of a nirsevimab immunisation programme was associated with a substantial reduction in AOM incidence among infants aged < 12 months, suggesting that RSV immunisation may reduce the burden of AOM in early childhood. WHAT'S KNOWN: • RSV is a major cause of morbidity during infancy, and acute otitis media is among its most frequent complications. • Nirsevimab has demonstrated high efficacy in preventing severe RSV disease in young children; however, its effect on outpatient RSV-related complications has not been well established. WHAT IS NEW: • This study provides population-based real-world evidence on the impact of nirsevimab on acute otitis media. • Following the implementation of nirsevimab prophylaxis, the incidence of acute otitis media among infants decreased significantly.
Indexed as
Identifiers
42855657What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.